Interleukin (IL)-17A Inhibitor as a Treatment for Darier Disease in the Pediatric Population
Bianka D Barajas Mendez1, Guadalupe Maldonado-Colin2, Lucia Achell Nava2
1Department of Dermatology, Universidad Nacional Autonoma de Mexico, Mexico City, MEX.
Abstract:
Darier disease is a genodermatosis that significantly affects patients' quality of life. We present the case of a 16-year-old patient whose quality of life remained markedly impaired despite systemic treatment. The patient experienced substantial clinical improvement in cutaneous lesions and quality of life following treatment with an interleukin (IL)-17A inhibitor. IL-17A inhibitors have demonstrated benefit in adults with Darier disease. In this case, we also observed therapeutic efficacy in a pediatric patient, supporting the relevance of this treatment approach in younger individuals. IL-17A inhibitors may play an important role in the management of Darier disease and represent a promising therapeutic option for pediatric patients, particularly in cases refractory to conventional therapies.
More Related Videos
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Conservation of Small Populations
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids


